Physician profile
Floyd D Fortuin
NPI 1861475436
$15,299.67
in general payments reported to CMS, 2019-2025
18 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,699 · 2020: $3,781 · 2021: $639 · 2022: $432 · 2023: $952 · 2024: $1,884 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,591 · Travel and Lodging: $2,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,590.67 |
| Travel and Lodging | $2,157.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $9,000.00 | 2019-2021 | |
| Edwards Lifesciences Corporation | $2,380.82 | 2019-2025 | Evoque, Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $1,623.35 | 2024-2025 | Tendyne, Portico, Triclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $893.04 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $299.36 | 2020-2025 | Watchman Access System |
| Medtronic, INC. | $272.05 | 2023-2025 | Corevalve Evolut R, Resolute Onyx |
| Novartis Pharmaceuticals Corporation | $262.46 | 2024 | |
| Medtronic Vascular, INC. | $217.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $123.17 | 2019 | |
| W. L. Gore & Associates, INC. | $119.76 | 2024 | Gore Cardioform Septal Occluder |
| Zoll Circulation INC | $48.27 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.27 | 2023 | |
| Cardiva Medical, INC. | $18.04 | 2025 | Cardiva Vascade 6/7f Vcs |
| Philips North America LLC | $13.30 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Fortuin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.